CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS

The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.

Saved in:
Bibliographic Details
Main Authors CHEN SHU PING, HO MENG FEN, CHEN YUNG FA, HENSCHKE JULIAN PAUL
Format Patent
LanguageEnglish
Korean
Published 06.08.2014
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SUGARS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.
Bibliography:Application Number: KR20147014572